目的 基于谱效关系联合效应成分指数（ECI）评价不同产地的苍术质量。方法 （1）采用高效液相色谱 （HPLC）法建立 30 批不同产地苍术的指纹图谱。采用脂多糖诱导大鼠小肠隐窝上皮细胞（IEC-6）细胞炎症损伤 模型，MTT 法检测 30 批不同苍术样品在炎症损伤模型 IEC-6 细胞中的细胞增殖率；利用灰色关联度分析、偏 最小二乘法判别分析（PLS-DA）等方法构建谱效关系筛选苍术的抗溃疡性结肠炎（UC）的药效成分。（2）采用 HPLC 法测定 30 批苍术中药效成分的含量；MTT 法测定药效成分在 IEC-6 细胞炎症损伤模型中的半数最大效 应浓度（EC50），结合自定义权重系数方法建立基于药效成分含量与药效值关联 ECI 的质量评价方法，并进行验 证。结果 （1）30 批苍术样品指纹图谱的相似度范围为 0.981～0.999，确定了 13 个共有峰。30 批不同苍术样 品在炎症损伤模型 IEC-6 细胞中的细胞增殖率存在差异，其中 W27 批次苍术样品的细胞增殖率最高 （72.02%），W21 批次苍术样品的细胞增殖率最低（28.81%）。谱效关系筛选出苍术 6 个抗 UC 药效成分（峰 2、 峰 4、峰 5、峰 7、峰 9、峰 11），经与对照品比对，指认 6 个峰分别为白术内酯Ⅲ、白术内酯Ⅱ、白术内酯 Ⅰ、β-桉叶醇、苍术素、苍术酮。（2）30 批苍术中白术内酯Ⅲ、白术内酯Ⅱ、白术内酯 I、β-桉叶醇、苍术素、 苍术酮的含量存在差异，其含量范围分别为 0.08～0.71、0.05～0.34、0.11～2.69、1.06～13.87、0.20～1.22、 0.08～2.07 mg·g-1 。白术内酯Ⅰ、白术内酯Ⅱ、苍术酮、β-桉叶醇、白术内酯Ⅲ、苍术素在炎症损伤模型 IEC-6 细胞中的 EC50分别为 38.87、38.28、35.47、33.85、32.76、28.87 µg·mL-1 。建立的苍术 ECI 能够代表苍术的抗 UC 药效作用及评价药材的质量，且与苍术抗 UC 药效作用呈显著正相关（r=0.728 4，P＜0.000 1）。结论 本 研究建立的谱效关系联合 ECI 法能够控制苍术质量，可客观反映不同产地苍术的质量及抗 UC 药效，可为中药 质量评价提供新方法。

Objective To evaluate the quality of Atractylodis Rhizoma from different origins based on spectrum-effect relationship combined with efficacy component index （ECI）. Methods（1） High performance liquid chromatography （HPLC） was used to establish fingerprint profiles of 30 batches of Atractylodis Rhizoma from different origins. A lipopolysaccharide-induced inflammatory injury model in rat small intestinal crypt epithelial cells （IEC-6） was established， and the cell proliferation rates of the 30 batches of Atractylodis Rhizoma samples in this model were detected by MTT assay. Grey relational analysis and partial least squares discriminant analysis （PLS-DA） were employed to construct the spectrum-effect relationship and screen for the anti-ulcerative colitis （UC） efficacy components of Atractylodis Rhizoma.（2） The contents of the identified efficacy components in the 30 batches of Atractylodis Rhizoma were determined by HPLC. The half-maximal effective concentration （EC50） of each efficacy component in the IEC-6 inflammatory injury model was determined by MTT assay. Combined with a custom weight coefficient method，a quality evaluation method based on the ECI，which associates component content with efficacy value， was established and validated. Results （1） The similarity of the fingerprint profiles of the 30 batches of Atractylodis Rhizoma samples ranged from 0.981 to 0.999，and 13 common peaks were identified. The cell proliferation rates of the 30 different Atractylodis Rhizoma samples in the inflammatory injury IEC-6 cell model varied. The Atractylodis Rhizoma sample from batch W27 showed the highest proliferation rate （72.02%），while batch W21 showed the lowest （28.81%）. The spectrum-effect relationship analysis screened six anti-UC efficacy components in Atractylodis Rhizoma （Peak 2， Peak 4， Peak 5， Peak 7， Peak 9， Peak 11）. By comparison with reference standards，these six peaks were identified as atractylenolide Ⅲ，atractylenolide Ⅱ，atractylenolide Ⅰ，β-eudesmol， atractylodin，and atractylon，respectively.（2） The contents of atractylenolide Ⅲ，atractylenolide Ⅱ，atractylenolide Ⅰ，β-eudesmol，atractylodin，and atractylon varied among the 30 batches of Atractylodis Rhizoma，with content ranges of 0.08-0.71，0.05-0.34，0.11-2.69，1.06-13.87，0.20-1.22，and 0.08-2.07 mg·g-1 ，respectively. The EC50 values of atractylenolide Ⅰ，atractylenolide Ⅱ，atractylon，β-eudesmol，atractylenolide Ⅲ，and atractylodin in the IEC-6 inflammatory injury cell model were 38.87，38.28，35.47，33.85，32.76，and 28.87 µg·mL-1 ，respectively. The established ECI for Atractylodis Rhizoma could represent its anti-UC efficacy and evaluate the quality of the medicinal material，showing a significant positive correlation with the anti-UC effect of Atractylodis Rhizoma （r=0.728 4， P＜0.000 1）. Conclusion The method combining spectrum-effect relationship and ECI established in this study can control the quality of Atractylodis Rhizoma and objectively reflect the quality and anti-UC efficacy of Atractylodis Rhizoma from different origins，providing a new method for the quality evaluation of traditional Chinese medicine.

R285.5

国家自然科学基金面上项目（82173935）；辽宁省教育厅重点攻关项目（JYTZD2023198）；中国博士后科学基金面上资助项目（2024M761255）； 国家中管局全国老药工（康廷国）传承工作室建设项目。